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The Parkinson’s disease-associated genes
ATP13A2 and SYT11 regulate autophagy
via a common pathway
Carla F. Bento1, Avraham Ashkenazi1, Maria Jimenez-Sanchez1 & David C. Rubinsztein1
Forms of Parkinson’s disease (PD) are associated with lysosomal and autophagic dysfunction.
ATP13A2, which is mutated in some types of early-onset Parkinsonism, has been suggested
as a regulator of the autophagy–lysosome pathway. However, little is known about the
ATP13A2 effectors and how they regulate this pathway. Here we show that ATP13A2
depletion negatively regulates another PD-associated gene (SYT11) at both transcriptional and
post-translational levels. Decreased SYT11 transcription is controlled by a mechanism
dependent on MYCBP2-induced ubiquitination of TSC2, which leads to mTORC1 activation
and decreased TFEB-mediated transcription of SYT11, while increased protein turnover is
regulated by SYT11 ubiquitination and degradation. Both mechanisms account for a decrease
in the levels of SYT11, which, in turn, induces lysosomal dysfunction and impaired degradation
of autophagosomes. Thus, we propose that ATP13A2 and SYT11 form a new functional net-
work in the regulation of the autophagy–lysosome pathway, which is likely to contribute to
forms of PD-associated neurodegeneration.
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I
ncreasing evidence has implicated autophagic dysregulation
and lysosomal impairment in a wide range of neurodegen-
erative disorders1. Neurons seem to be particularly susceptible
to lysosomal dysfunction, as over two-thirds of lysosomal storage
diseases manifest with central nervous system dysfunction2.
In the particular case of Parkinson’s disease (PD), several disease-
animal models and post-mortem brain samples of PD patients
have revealed lysosomal dysfunction and accumulation of non-
degraded autophagosomes in neurons, and pharmacological or
genetic restoration of lysosomal degradation in such models
resulted in increased autophagosome clearance and decreased
dopaminergic cell death3–5.
The ATP13A2 gene (also known as PARK9), which encodes a
lysosomal P5-type ATPase, is mutated in autosomal recessive
forms of early-onset Parkinsonism, such as the Kufor–Rabek
syndrome, and thus appears to link lysosomal dysfunction
and Parkinsonism5–8. Decreased levels of ATP13A2 or loss-of-
function mutations that destabilize the protein in the endoplasmic
reticulum (depleting it from the lysosome) impairs degradation of
lysosomal substrates, diminishes lysosomal-mediated clearance of
autophagosomes in dopaminergic neurons, and induces misfolding
and accumulation of a-synuclein, a major protein that accumulates
in neurons in PD5,8,9.
Several other genes, some of them still needing functional
validation, have also been identiﬁed in different genome-wide
association studies (GWAS) as new PD risk loci. Synaptotagmin 11
(SYT11) emerged as one of these putative PD-associated genes10–13
(also indicated as a candidate gene for susceptibility to
schizophrenia14), which was also interestingly suggested as a
new possible interactor of ATP13A2 in a split-ubiquitin yeast
two-hybrid study15. Although SYT11 has been scarcely studied and
reported in the literature, it belongs to a family of transmembrane
proteins generally involved in vesicular fusion, trafﬁcking and
exocytosis16, and it was interestingly shown to localize in
lysosomes in bone marrow-derived macrophages17, suggesting
that it might regulate mechanisms relevant for autophagy and
lysosome biology. Accordingly, we aimed to test whether
ATP13A2 and SYT11 act in a common pathway and whether
SYT11 also impacts on autophagy and/or lysosomal function, in
order to provide new mechanistic insights into molecular
mechanisms in PD. Here we show that ATP13A2 regulates
SYT11 at both transcriptional and post-translational levels and that
ATP13A2-mediated autophagy responses are dependent on
SYT11, indicating that these two genes form a new functional
network regulating the autophagy–lysosome pathway.
Results
ATP13A2 depletion decreases SYT11 mRNA expression. SYT11
recently emerged as a new PD-associated gene, which was also
suggested as a possible interactor of ATP13A2 (ref. 15). Although
we were not able to detect an obvious physical interaction
between SYT11 and ATP13A2 by blotting (but cannot exclude
such an interaction as suggested by our mass spectrometry data)
(Supplementary Fig. 1a,b), our initial results interestingly sug-
gested that SYT11 is a downstream target of ATP13A2, since
ATP13A2 knockdown decreased SYT11 mRNA levels in HeLa
cells (Fig. 1a; Supplementary Fig. 1c), SH-SY5Y cells
(Supplementary Fig. 1d) and primary neuronal cultures (Fig. 1b;
Supplementary Fig. 1e). Although we could not examine SYT11
protein levels in human cells, as the antibodies we purchased did
not work, we could conﬁrm in mouse primary cultures of neu-
rons that decreased SYT11 mRNA levels are accompanied by
decreased SYT11 protein levels under the knockdown of
ATP13A2 (Fig. 1c; Supplementary Fig. 1e). In agreement,
ATP13A2 overexpression had the reverse effect, increasing the
mRNA levels of SYT11 (Fig. 1d; Supplementary Fig. 1f), while
overexpression of two PD-associated ATP13A2 mutants (3057
delC and 1632_1653dup22 mutants, henceforth delC and i16
mutants, respectively)7 were not able to increase the mRNA levels
of SYT11, compared with the wild-type (WT) form (Fig. 1e;
Supplementary Fig. 1f). These mutants have been described
to be retained in the endoplasmic reticulum, being unable to
reach the lysosome (Fig. 1f), suggesting that a fully functional
ATP13A2 complex is needed at the lysosome to ﬁnely
regulate SYT11 mRNA expression. (One should note that in
our system, ATP13A2 loss-of-function mutants do not
produce the same phenotype as ATP13A2 depletion conditions,
since experiments were performed in HeLa cells, where
endogenous background levels of ATP13A2 WT are sufﬁcient
to ensure normal activity of ATP13A2; this means that
overexpression of loss-of-function mutants can only be
compared with ATP13A2 WT overexpression conditions.) The
changes observed in the regulation of SYT11 transcription by
ATP13A2 could not be attributed to apoptosis induction, as
manipulation of ATP13A2 levels did not change the number of
non-apoptotic and apoptotic cells as compared with control cells
(Supplementary Fig. 1g).
Regulation of SYT11 mRNA by ATP13A2 occurs via TFEB. To
understand how SYT11 expression was regulated by ATP13A2,
we analysed the DNA sequence of the human SYT11 gene and
found two putative binding sites in its promoter for the tran-
scription factor EB (TFEB) (Supplementary Fig. 2a), a master
regulator of lysosomal biogenesis18. The sequence of these sites
fulﬁlled the criteria for CLEAR domains (TFEB-binding
sequences) in promoter regions of genes: (i) high homology to
the CLEAR consensus sequence 50-GTCACGTGAC-30 and (ii)
the putative motifs should be located within 1,000 bp upstream
and 200 bp downstream of the transcription start site18,19.
As depicted in Supplementary Fig. 2a, the two plausible CLEAR
sites in the SYT11 promoter region are at  965 bp (site 1) and
 543 bp (site 2) from the transcription start site, with site 2
revealing a high homology to the CLEAR consensus sequence
(8 in 10 nucleotides). Interestingly, nuclear/cytosolic fractionation
experiments revealed that ATP13A2 knockdown decreased the
levels of TFEB in the nucleus (Fig. 2a), while ATP13A2
overexpression increased the nuclear TFEB levels (Fig. 2b),
phenomena also observed by ﬂuorescence microscopy (Fig. 2c).
These changes were not due to signiﬁcant changes in the
total levels of TFEB (Supplementary Fig. 2b). This was further
conﬁrmed in primary mouse neuronal cultures, where ATP13A2
knockdown decreased the levels of TFEB in the nucleus (Fig. 2d,e;
Supplementary Fig. 1e). Cytosolic and nuclear levels of
ZKSCAN3, a master transcriptional repressor of autophagy that
is thought to oppose TFEB, did not appear to be signiﬁcantly
changed by the manipulation of ATP13A2 levels (Supplementary
Fig. 2c). Real-time PCR data allowed us to conﬁrm that TFEB
knockdown indeed decreased SYT11 mRNA levels upon
ATP13A2 overexpression (Fig. 2f) (and also under basal
conditions—Supplementary Fig. 2d,e), whereas overexpression
of the WT or a constitutively active mutant (S142A) form of
TFEB increased the SYT11 mRNA levels under ATP13A2-
knockdown conditions (Fig. 2g), indicating that TFEB plays a role
in the regulation of SYT11 mRNA expression by ATP13A2.
Chromatin immunoprecipitation experiments also revealed that
TFEB binds positively and speciﬁcally to the CLEAR domain at
site 2 of SYT11 promoter and that ATP13A2 overexpression
potentiated this binding (Fig. 2h). TFEB binding to SYT11 site 1
was not conﬁrmed due to high unspeciﬁc binding of IgGs to
chromatin at this region (Supplementary Fig. 2f). In agreement,
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ATP13A2 overexpression increased the transcriptional activation
of the SYT11 promoter, whereas abrogation of TFEB-binding site
2 within the SYT11 promoter signiﬁcantly reduced this effect
(Fig. 2i). The fact that this effect was not fully abolished indicates
that other putative TFEB-binding sites or other transcription
factors might be involved in the regulation of SYT11 transcription
under these conditions. Thus, the regulation of SYT11 by
ATP13A2 appears to be mediated, at least in part, by TFEB
through its binding to CLEAR-site 2 in SYT11 promoter.
Serine 142 of TFEB has been characterized as a key residue for
phosphorylation and regulation of TFEB by the mammalian
target of rapamycin complex 1 (mTORC1), which is known to
negatively regulate TFEB activity by impairing its shuttling into
the nucleus20,21. Since overexpression of S142A TFEB was more
effective than WT TFEB in increasing the SYT11 mRNA levels
under ATP13A2-knockdown conditions (Fig. 2g), we considered
that mTORC1 may be involved in the regulation of SYT11
mRNA expression by TFEB. Consistent with this model,
ATP13A2 depletion induced a slight upwards shift of TFEB
mobility on SDS–PAGE (polyacrylamide gel electrophoresis),
compatible with increased phosphorylation, which was blunted
by torin-1, a well-established mTOR inhibitor22 (Fig. 2a). Torin-1
treatment also tended to restore the cytosolic/nuclear TFEB ratio
under the knockdown of ATP13A2 (Fig. 2a), suggesting that
ATP13A2 regulates TFEB through mTORC1. In parallel, confocal
microscopy data further indicated increased co-localization of
phosphorylated mTOR with lysosomes/LAMP1-positive vesicles
in ATP13A2-knockdown cells (Fig. 3a). This supports a model
where ATP13A2 inhibition impairs TFEB activity via increased
mTORC1 activity, as the latter requires localization of the
mTORC1 complex at lysosomes20,23. In agreement, knockdown
of ATP13A2 increased the phosphorylation of p70S6K, a
well-known mTORC1 substrate frequently used as an mTORC1
activity reporter24, not only in HeLa cells (Fig. 3b, left panel) but
also in primary neuronal cultures (Fig. 3c), while ATP13A2
overexpression decreased p70S6K phosphorylation status (Fig. 3b,
right panel), indicating increased and decreased mTORC1
activity, respectively. In addition, overexpression of delC or i16
ATP13A2 mutants was ineffective in decreasing the levels of
phospho-p70S6K, as compared with the WT form (Fig. 3d),
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Figure 1 | ATP13A2 regulates the mRNA expression of SYT11. (a) The mRNA levels of SYT11 and GAPDH in Control and ATP13A2-knockdown HeLa cells
were measured by real-time PCR. The experiment (with triplicates) was repeated an additional two times and all were similarly signiﬁcant. (b) Primary
cultures of mouse neurons transduced with Control or ATP13A2 lentiviral shRNAs for 5 days were used to measure the mRNA levels of SYT11 and GAPDH
by real-time PCR. The graph shows the mean±s.d. of four independent experiments. *Po0.05 (two-tailed paired Student’s t-test). (c) Primary cultures of
mouse neurons transduced with Control or ATP13A2 lentiviral shRNAs (#A and #B) were lysed and blotted against SYT11 and actin. A representative
experiment with triplicates is shown. (d) The mRNA levels of SYT11 and GAPDH in HeLa cells transfected with empty pcDNA3.1 or ATP13A2 WT were
measured by real-time PCR. A representative experiment (with triplicates) of three similarly signiﬁcant independent experiments is shown. (e) HeLa cells
transfected with empty pcDNA3.1, ATP13A2 WT, ATP13A2 delC or ATP13A2 i16 mutants were used to measure the mRNA levels of SYT11 and GAPDH by
real-time PCR. The experiment was repeated and both experiments were similarly signiﬁcant. (f) HeLa cells transfected with V5-tagged ATP13A2 WT,
ATP13A2 delC or ATP13A2 i16 constructs were immunostained against V5 and LAMP1 and imaged using confocal microscopy (scale bar 10mM). Unless
otherwise stated, all the graphs represent mean±s.d. and statistical signiﬁcance was determined using two-tailed unpaired Student’s t-test. **Po0.01;
***Po0.001; NS, not signiﬁcant.
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suggesting that lysosomal localization of ATP13A2 is required for
mTORC1 regulation. Of interest, prolonged mTORC1 inhibition
by rapamycin was able to rescue the SYT11 mRNA levels under
the knockdown of ATP13A2 (Fig. 3e). Thus, ATP13A2 appears to
positively regulate SYT11 transcription via TFEB by inhibiting
mTORC1.
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designed against the putative TFEB-binding site 2 on the promoter of SYT11 were used for qPCR. The TFEB binding to SYT11 promoter is represented.
The experiment (with triplicates) was repeated and both experiments were similarly signiﬁcant. (i) HeLa cells were transfected with empty pcDNA3.1 or
ATP13A2 WT simultaneously with WT or CLEAR-site 2 mutant SYT11 promoter-GLuc/SEAP. Medium was collected 48 h later. Secreted Gaussia
luciferase and SEAP were measured. A representative experiment (with triplicates) of two independent experiments is shown. All the graphs represent
mean±s.d. and statistical signiﬁcance was determined using two-tailed unpaired Student’s t-test. *Po0.05, **Po0.01; #Po0.05, ##Po0.01. CF, cytosolic
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Regulation of mTORC1 by ATP13A2 occurs via TSC2. We
hypothesized that the regulation of mTORC1 by ATP13A2 may
have been due to the ATP13A2-MYCBP2 (MYC-Binding Protein
2) interaction previously reported15, since the latter protein is an
ubiquitin ligase for Tuberous Sclerosis Complex 2 (TSC2)25,
which in turn is a well-established negative regulator of mTORC1
(ref. 26). Indeed, a proximity ligation assay, which yields a
signal when two proteins of interest are within 40 nm of each
other, indicated that a fraction of MYCBP2 resides in the vicinity
of ATP13A2 (Fig. 4a; Supplementary Fig. 3a). The interaction
between ATP13A2 and MYCBP2 was also conﬁrmed by
endogenous ATP13A2 immunoprecipitation, where some
TSC2 was also co-immunoprecipitated (Fig. 4b). A link
between ATP13A2 and mTORC1 function via TSC2 was also
strengthened by the observations that ATP13A2 knockdown,
in HeLa cells or mouse neurons, decreased the levels of
TSC2 (Fig. 4c,d), in parallel to the increased mTORC1 activity
(Fig. 3b,c), and that ATP13A2 WT overexpression increased the
levels of TSC2, while the delC and i16 mutants were unable to
change the levels of this mTORC1 negative regulator (Fig. 4e). It
should be noted that TSC2 phosphorylation followed the same
trend as total TSC2 under the knockdown of ATP13A2 (Fig. 4c),
suggesting that downstream signalling is likely to be affected due
to lower levels of total TSC2 rather than unbalanced TSC2
phosphorylation. In agreement, depletion of ATP13A2 decreased
TSC2 half-life (Fig. 4f) and induced TSC2 ubiquitination
(Fig. 4g), indicating that this perturbation altered TSC2 levels
by affecting protein stability. Consistent with our model where
ATP13A2 inhibits MYCBP2-dependent TSC2 degradation, which
decreases mTORC1 activity, MYCBP2 depletion (Supplementary
Fig. 3b) re-established TSC2 ubiquitination status (Fig. 4g) and
normalized the levels of TSC2 and the activity of mTORC1 under
the knockdown of ATP13A2 (Fig. 4h). It should be noted that
ATP13A2 depletion conditions are characterized by increased
levels of LC3-II (Fig. 4h), which correlate with autophagosome
numbers27, consistent with previous studies showing impaired
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lysosome function and impaired autophagosome degradation in
ATP13A2-depleted cells5,8. Partial rescue of LC3-II levels by
MYCBP2 knockdown in ATP13A2-depleted cells (Fig. 4h)
suggests that ATP13A2 regulates the autophagy–lysosome
pathway, at least in part, via TSC2 and MYCBP2. The fact that
ATP13A2 depletion did not appear to obviously change the
extent to which MYCBP2 interacts with TSC2 (Fig. 4i) suggests
that ATP13A2 is likely to regulate MYCBP2 activity towards
TSC2 rather than assisting the interaction between the two
proteins.
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using primary antibodies against ATP13A2 and MYCBP2. Cells were imaged by epiﬂuorescence microscopy (scale bar, 10mM). PLA negative controls are
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ATP13A2 and SYT11 depletion block autophagy. Since SYT11
expression is regulated by ATP13A2, we tested whether SYT11
and ATP13A2 coordinately regulate autophagy and the lysosome.
We ﬁrstly employed knockdown strategies to understand whether
SYT11 regulates autophagy, by measuring the numbers of LC3
vesicles and the levels of LC3-II on SDS–PAGE gels. By
overexpressing a GFP-tagged LC3 construct, we observed
that SYT11 knockdown signiﬁcantly increased the number of
GFP-LC3 vesicles, suggesting autophagy modulation (Fig. 5a;
Supplementary Fig. 4a,b). An increase of the numbers of LC3
vesicles may reﬂect either enhanced autophagosome synthesis, or
decreased autophagosomal clearance by the lysosome. To dis-
tinguish between these scenarios, one can measure LC3-II levels
under conditions where autophagosome degradation is inhibited,
for example, by baﬁlomycin A1 (BAF A1), a potent proton pump
inhibitor that blocks lysosomal degradation. Since LC3-II levels
were elevated by SYT11 knockdown in the absence of BAF A1,
but not in its presence (where any changes would reﬂect altered
autophagosome biogenesis) (Fig. 5b; Supplementary Fig. 4c,d), we
concluded that SYT11 knockdown blocks LC3-II/autophagosome
clearance. This occurred both in full-nutrient (Fig. 5b) and
starvation conditions (Fig. 5c), which stimulates autophagosome
biogenesis. (Note that the amount of LC3-I detected by the
antibody we used in HeLa cells is very low and can only be seen
using exposures that cause oversaturation of LC3-II bands. This is
not an issue, as the convention is to relate LC3-II to a loading
control like actin, and not LC3-I (ref. 24). We also present the
data with and without BAF A1 using different exposures, and
thus distinct panels, to allow band exposures in the linear range,
which is often impossible if one shows the same exposure of the
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samples with and without BAF A1 (refer to the full blot image in
Supplementary Fig. 4d)). This result was further conﬁrmed by the
knockdown of SYT11 in SK-N-SH human neuroblastoma cells
(Fig. 5d) and primary cultures of mouse neurons (Fig. 5e;
Supplementary Fig. 4e). Consistent with these data, the clearance
rate of the autophagic substrate P62 was decreased by the
knockdown of SYT11 after switching off transgene expression in
an inducible GFP-P62 HEK293 cell line (Fig. 5f).
Autophagic ﬂux can also be assessed using an mRFP-EGFP-
LC3 stable cell line, which exploits the properties of GFP and
RFP; GFP ﬂuorescence is quenched by the low pH of the
lysosome when autophagosomes fuse with lysosomes, while RFP
ﬂuorescence is more stable in acidic compartments, which
means that autophagosomes are labelled yellow (greenþ red)
and autolysosomes are red only28. Using this cell line, we
conﬁrmed that SYT11 knockdown increased the proportion of
yellow vesicles (autophagosomes), without a concomitant
increase of the numbers of red-only vesicles (autolysosomes),
suggesting blockage of the maturation of autophagosomes into
autolysosomes (Fig. 5g,h). In agreement, automatic counting and
analysis also showed a signiﬁcant increase of the size of the green
vesicles (Fig. 5h).
A blockage in LC3-II degradation can occur at any step after
autophagosome formation and can be induced by factors such as
delayed trafﬁcking of the autophagosomes to the lysosomes,
reduced fusion between both compartments and/or impaired
lysosomal proteolytic activity. Impairment of autophagosome
recruitment to the lysosomes can be assessed by determining LC3
co-localization with the lysosome/late endosome marker LAMP1.
Confocal analysis showed that SYT11 knockdown did not
decrease the co-localization of both markers, suggesting that
coalescence of both compartments is not affected (Fig. 6a). SYT11
knockdown appeared indeed to increase the number of large
LAMP1 vesicles ﬁlled by LC3, indicating that recruitment and
fusion are not compromised (Fig. 6a). Interestingly, microscopy
images revealed abnormal lysosomal clustering close to the
perinuclear region after SYT11 knockdown (Fig. 6b), which
suggested lysosomal dysfunction. pH and enzymatic activity of
the lysosome are well-established markers of its function.
Compatible with this assumption, SYT11 knockdown increased
the endosomal/lysosomal pH (Fig. 6c; Supplementary Fig. 4f,g)
and decreased the activity and the levels of the mature form of
cathepsin-L (Fig. 6d,e), which are both pH-dependent29,30,
indicating that SYT11 blocks autophagosome clearance by
compromising the lysosomal function.
We were struck that SYT11 and ATP13A2 knockdowns
phenocopied each other in many respects. For instance, we
observed (as shown by others previously5,8) that ATP13A2
knockdown impaired autophagosome degradation, both in HeLa
cells (Fig. 6f; Supplementary Fig. 4h) and primary mouse
neuronal cultures (Fig. 6g), induced lysosomal clustering
(Fig. 6h) and increased the lysosomal pH (Fig. 6i). Interestingly,
simultaneous knockdown of ATP13A2 and SYT11 did not
synergize to additively increase LC3-II levels under basal
conditions, as compared with the individual knockdowns
(Fig. 7a), reinforcing the idea that these genes might act on
autophagy through the same molecular pathway.
ATP13A2 depletion blocks autophagy via SYT11. To determine
whether the autophagy blockage phenotype observed under
ATP13A2-depleting conditions was mediated by downregulation
of SYT11, we overexpressed SYT11 in ATP13A2-knockdown cells
and measured the levels of A53T mutant a-synuclein (the
clearance of which is highly dependent on autophagy31), in
parallel to the levels of LC3-II. SYT11 overexpression was indeed
able to reduce the elevated LC3-II levels caused by the
knockdown of ATP13A2 to normal levels (Fig. 7b,c), suggesting
that SYT11 overexpression re-established the autophagic ﬂux and
that ATP13A2-induced blockage of autophagy is triggered
by decreased expression of SYT11. Concomitantly, SYT11
overexpression decreased and normalized the levels of a-
synuclein A53T that were elevated in ATP13A2-knockdown
cells (Fig. 7d), indicating that re-introduction of SYT11 in
conditions characterized by decreased levels of ATP13A2 induced
increased clearance of a-synuclein by augmenting the autophagic
activity. This effect was autophagy-dependent, as these
manipulations were ineffective in changing the levels of a-
synuclein A53T in autophagy-incompetent cells (ATG16L1-
deﬁcient cells, generated by CRISPR/Cas9 editing, that are
unable to efﬁciently produce LC3-II) (Fig. 7e,f). Re-
establishment of the autophagic ﬂux by the overexpression of
SYT11 under ATP13A2-knockdown conditions was accompanied
by normalization of the endo-lysosomal pH (Fig. 7g;
Supplementary Fig. 5a) indicating that SYT11 regulates the
status of the lysosome. In agreement with our model, we observed
that TFEB WT or TFEB S142A mutant overexpression also
decreased the levels of a-synuclein A53T in ATP13A2-
knockdown cells (Fig. 7h), consistent with increased autophagy-
mediated clearance of a-synuclein. The observation that TFEB
overexpression not only rescued the levels of a-synuclein A53T
under the knockdown of ATP13A2, but also decreased its levels
below to the control levels is likely to be explained by the fact that
TFEB also induces autophagy32. We also observed that SYT11
manipulation itself did not change the levels of TFEB
(Supplementary Fig. 2b) and that SYT11 overexpression under
ATP13A2-knockdown conditions did not appear to affect the
sub-cellular localization of TFEB (Supplementary Fig. 5b),
indicating that SYT11 acts indeed downstream of ATP13A2
and TFEB in the network described here. Of interest, ATP13A2
or SYT11 short-term depletion conditions did not signiﬁcantly
affect cellular viability (Supplementary Fig. 1g). However, viability
became signiﬁcantly compromised when cells were insulted with
a-synuclein A53T overexpression (Supplementary Fig. 5c),
indicating that these two proteins are indeed important for the
clearance of a-synuclein and the survival of cells under
pathological conditions that are relevant to PD.
Although mTORC1, TFEB and other players downstream of
ATP13A2 will have other effects impacting on disease, it is
striking that ATP13A2 and SYT11 knockdowns phenocopied
each other in multiple respects and that SYT11 robustly rescued
the autophagy blockage phenotype caused by ATP13A2 depletion
(Fig. 7b,d). This indicated that SYT11 somehow overwhelms all
the other autophagy–lysosomal proteins putatively regulated by
AP13A2 via TFEB and that SYT11 is indeed a critical
downstream target of ATP13A2 in the regulation of autophagy.
Therefore, we considered that the regulation of SYT11 levels by
ATP13A2 may involve both transcriptional and additional
post-transcriptional processes. Indeed, apart from regulating
SYT11 transcription, we found that ATP13A2 also regulated
SYT11 protein stability. While ATP13A2 knockdown decreased
SYT11 protein levels (Fig. 8a), ATP13A2 overexpression had the
opposite effect (Fig. 8b). It should be noted that these changes
are not due to transcriptional regulation, as SYT11
protein levels were measured by using a tagged-SYT11 expression
construct driven by an exogenous promoter. In agreement with
the idea that ATP13A2 is likely to regulate SYT11 post-
translationally, we observed that ATP13A2 depletion decreased
the half-life of SYT11 (Fig. 8c). We also observed that this
regulation occurs regardless of whether SYT11 is N- or
C-terminal-, GFP- or c-myc-tagged (compare Fig. 8a,c and
Supplementary Fig. 6a,b). Consistently, ATP13A2 overexpression
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decreased SYT11 ubiquitination (Fig. 8d), while ATP13A2
knockdown increased SYT11 ubiquitination (Fig. 8e), indicating
decreased protein stability. Increased SYT11 ubiquitination under
ATP13A2-depleting conditions was also observed using an
antibody that speciﬁcally recognizes K48-linked polyubiquitin
chains (Fig. 8e), which is compatible with proteasome-dependent
degradation. In agreement, proteasome inhibition increased
the half-life of SYT11 under the knockdown of ATP13A2
(Fig. 8f; Supplementary Fig. 6c), suggesting that ATP13A2
regulates SYT11 ubiquitination and degradation by a mechanism
dependent on the proteasome. Overall, the fact that
ATP13A2 regulates SYT11, not only at the transcriptional level,
but also at the post-translational level provides a plausible
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explanation for the SYT11-dependency of ATP13A2-mediated
autophagy responses.
Discussion
Lysosomal and autophagy impairment appear to be hallmarks of
PD; however the mechanisms involved in these dysfunctions are
still poorly understood. Here we describe a new functional
network established by ATP13A2 and SYT11, providing some
new understanding into the putative mechanisms underlying the
lysosomal and autophagy impairment phenotypes observed in
some models of the disease. While our data suggest that
ATP13A2 and SYT11 are in the same pathway, this does not
mean they act in the same functional complex. For instance, these
two proteins certainly have very distinct roles. Accordingly, we
found for the ﬁrst time that ATP13A2 downregulation decreases
TSC2 levels, by a mechanism dependent on MYCBP2-induced
ubiquitination, which in turn activates mTORC1, inhibits TFEB
translocation to the nucleus and compromises TFEB-mediated
transcription of SYT11. We observed that ATP13A2 also
promotes ubiquitination of SYT11 and its degradation in a
proteasome-dependent manner. Both mechanisms account for a
pronounced decrease of SYT11 levels in cells, which in turn
causes lysosomal dysfunction, impairment of autophagosomes
degradation and a-synuclein A53T accumulation (Fig. 9), all
being PD hallmarks.
Although we were able to show that ATP13A2, MYCBP2 and
TSC2 co-immunoprecipitate together (conﬁrming previous
results15,25), we did not observe signiﬁcant changes in the
physical interaction between MYCBP2 and TSC2 when ATP13A2
was depleted, suggesting that ATP13A2 is likely to act as a
positive regulator of TSC2 through inactivation of MYCBP2
E3-ligase activity towards TSC2, rather than by affecting the
afﬁnity between the two proteins. For instance, ATP13A2 can
regulate zinc homeostasis33,34, and MYCBP2 is an E3 ligase with
zinc requirements due to the presence of B-box-type zinc ﬁnger
and RING-type zinc ﬁnger domains in its sequence (UniProt
accession number O75592). Therefore, one possibility is that
ATP13A2 indirectly regulates MYCBP2 activity by controlling
zinc availability and/or establishing zinc microenvironments in
the vicinity of the complex.
The regulation of SYT11 ubiquitination by ATP13A2 observed
here also requires further understanding. SYT11 was previously
shown to be ubiquitinated by Parkin35, which is a RING-type E3
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ligase that also has zinc requirements (UniProt accession number
O60260); however, HeLa cells have little endogenous Parkin
expression, compared with neuronal cells36. Considering the
observation that ATP13A2 regulates SYT11 levels not only in
neurons but also in HeLa cells, we speculate that: (1) a little
Parkin expression is enough to sustain SYT11 ubiquitination in
HeLa cells, or (2) ATP13A2 induces SYT11 ubiquitination by
signalling through a Parkin-independent mechanism (even in
neurons) or (3) another ubiquitin ligase can compensate for the
lack of Parkin in non-neuronal cells.
It is interesting to note the existence of mechanistic parallels
between various pathways known to be impaired in PD.
Mitophagy is indeed one of these pathways, where
PINK-1-dependent recruitment of Parkin to damaged
mitochondria induces ubiquitination of mitochondrial membrane
proteins (for example, mitofusin-2 or MFN2), which serves as a
signal to recruit the autophagy machinery and sustain mitochon-
dria degradation37. On the other hand, the pathway described
here involves regulation of the lysosomal and autophagic
activities by a mechanism where ATP13A2 controls the mRNA
and protein levels of SYT11 (by several ubiquitination-dependent
events), which is likely to regulate, in turn, the shuttling of key
proteins and enzymes to the lysosome necessary for its normal
function. Faults in these pathways are therefore expected to
culminate in the accumulation of autophagy substrates such as
damaged/aged mitochondria and a-synuclein aggregates, which
are known to enhance susceptibility to neuronal cell death.
Interestingly, ATP13A2 depletion was observed to compromise
mitochondrial function and clearance due to reduced autophagic
ﬂux38, emphasizing the possible crosstalk between the PINK1/
Parkin and ATP13A2/SYT11 pathways in PD.
Despite the fact that TFEB has been shown to have a key role in
the modulation of several lysosome-related diseases3,39,40, no TFEB
disease-associated variants have been found so far. However, the
fact that ATP13A2 appears in this work as a new TFEB regulator
provides a hypothetical and indirect pathophysiological context for
the plausible contribution of TFEB to the development of PD and,
eventually, other neurodegenerative disorders.
mTORC1 is a key regulator of protein translation, whose
activation is canonically associated with increased protein
synthesis and levels, and also regulates speciﬁc cellular pathways
by controlling complex transcriptional programs. A genomic
approach to identify mTORC1-regulated transcripts surprisingly
identiﬁed not only mTORC1-induced genes but also mTORC1-
repressed genes41. In addition, mTORC1 activation was also
shown to positively control some cytoplasmic 50-30 mRNA
degradation mechanisms42 and inhibit synthesis of certain
transcripts by inactivation of speciﬁc transcription factors, such
as TFEB in mammals20, and Rim15, Msn2/4 and Gln3 in yeast42.
This shows that transcriptional regulation by mTORC1 is not as
linear and simple as once thought, and that mTORC1 inhibition
by rapamycin increases the mRNA levels of certain genes, like
SYT11 in the speciﬁc case of this work. Consistent with our
model, rapamycin was interestingly observed by others to rescue
autophagic defects in ATP13A2-depleted cells38. However, these
autophagic defects were attributed to early autophagy inhibition
rather than to autophagy late blockage38. Although we do not
exclude the possibility of simultaneous early inhibition of
autophagy (as mTORC1, a well-known autophagy inhibitor, is
activated by the knockdown of ATP13A2) and autophagy late
blockage, the authors measured the autophagic ﬂux by treating
cells with a non-saturating concentration (5 nM) of baﬁlomycin
A1, which is not sufﬁcient to robustly block autophagosome–
lysosome fusion and accurately measure autophagic ﬂux43. In
addition, numbers of autophagosomes and autolysosomes were
the only RFP-GFP-LC3 assay readout considered; size of vesicles
is also an important readout for identifying autophagy late
blockers, as large size and intensity might mask the total number
of vesicles, which cannot fuse and/or be degraded in this scenario.
The concomitant occurrence of mTORC1 hyperactivation and
lysosomal dysfunction resulting from ATP13A2 knockdown may
be surprising, as integrity of the lysosomal proton-pump ATPase
has been widely proposed to be necessary for mTORC1
activation, in conjugation with Ragulator and Rag GTPases in
the lysosomal membrane44. However, several independent groups
have shown that abnormal lysosomal pH can increase activation
of mTORC1 in some cell lines, at least45,46. In addition, FCCP, an
ionophore capable of dissipating the lysosomal proton gradient
without interfering with the V-ATPase, does not appear to
abrogate amino-acid-induced binding of Raptor (the Regulatory-
Associated Protein of mTORC1) to RagB in lysosomes,
suggesting that maintenance of lysosomal proton gradient by
V-ATPase is dispensable for mTORC1 activation in lysosomes47
and that mTORC1 can be activated in the context of increased
lysosomal pH. Thus, our data are not inconsistent with the
literature, since mTORC1 activation/hyperactivation does not
require full lysosomal function.
Although this is the ﬁrst study to ascribe a role to SYT11 in the
regulation of the autophagy–lysosome pathway, this is not of
complete surprise. SYTs constitute a family of proteins that are
generally involved in calcium-dependent vesicular fusion,
trafﬁcking and exocytosis, having a major role in the regulation
of neurotransmitter release and hormone secretion by virtue of
the calcium-binding afﬁnity of their C2 motifs. However, SYT11
is unexpectedly thought to be, at least in part, calcium-
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Figure 9 | Model proposed on how ATP13A2 and SYT11 establish a
common network that regulates the autophagy–lysosomal pathway.
Orange arrows identify the sequence of events that occur when ATP13A2 is
depleted from cells, which in turn leads to depletion of SYT11, while green
edges identify the sequence of events when ATP13A2 and SYT11 remain
under steady-state conditions. Overall, we propose that ATP13A2 depletion
decreases TSC2 levels, by a mechanism dependent on MYCBP2-induced
ubiquitination, which in turn induces activation of mTORC1 and decreased
TFEB-mediated transcription of SYT11. In parallel, ATP13A2 depletion
induces SYT11 ubiquitination and degradation. Both events contribute to a
decrease of SYT11 levels, which induces lysosomal dysfunction, autophagy
blockage and increased accumulation of a-synuclein A53T.
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insensitive48–50, suggesting speciﬁc and unpredicted roles and
further levels of regulation. (As an example, SYT11 has been
shown to function as a negative regulator of endocytosis,
controlling vesicle retrieval, while Ca2þ -binding SYTs are
normally seen as positive regulators of endocytosis51).
Therefore, we postulate that SYT11 is likely to affect autophagy
either by inhibiting the fusion between autophagosomes and
lysosomes (as SYT proteins are canonically implicated in
vesicular fusion events by assisting SNAREs) or by directly
regulating the activity of lysosomes (for example, by controlling
the delivery of hydrolases or V-ATPase components to the
lysosome from the Golgi compartment). This last hypothesis
sounds particularly plausible not only because coalescence of
LAMP-1-positive and LC3-positive vesicles did not appear to be
affected by SYT11 depletion but also because the lysosomal pH
and enzymatic activity were both observed to be disturbed under
SYT11-depleting conditions. In addition, other SYTs are
implicated in the recruitment of LAMP1 and V-ATPase to
phagosomes52,53, indicating that SYT11 depletion might impact
the function of degradative vesicular compartments within the
cell.
In conclusion, our data shows that ATP13A2 regulates SYT11
at both transcriptional and post-translational levels. We found
that mRNA expression of SYT11 is regulated by the TSC2/
mTORC1/TFEB transcriptional axis, while SYT11 protein levels
are regulated by ubiquitination and proteasomal-dependent
degradation mechanisms. Defects in this pathway are associated
with lysosomal dysfunction, autophagy impairment and accumu-
lation of a-synuclein A53T, which are plausible contributors to
PD pathogenesis. Therefore, while other studies are required to
elucidate further aspects of the pathway and the disease, we
believe this work fosters solid ground for future investigations.
Methods
Cell lines. HeLa, SH-SY5Y, SK-N-SH (from ATCC) and GFP-P62 HEK293 Flp-In
T-REx cells (gift from Dr Terje Johansen)54 were maintained at 37 C and 5% CO2
and cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (4.5mg l 1 of
glucose) supplemented with 10% FBS, 2mM L-glutamine and 100Uml 1
penicillin and 100mgml 1 streptomycin (all the components were obtained from
Sigma Aldrich). HeLa cells stably expressing mRFP-EGFP-LC3 were cultured also
in the presence of geneticin at a concentration of 500mgml 1, while the GFP-P62
HEK293 Flp-In T-REx cells were maintained in the presence of 7.5 mgml 1
blasticidin and 100 mgml 1 hygromycin. All the lines were regularly tested for
mycoplasma contamination.
Reagents. The following primary antibodies have been used in this work: mouse
anti-ATP13A2 (#110-41486, Novus Biologicals); mouse anti-cathepsin L clone 22
(#611084, BD Transduction Laboratories; immunoblotting concentration 1:300);
mouse anti-Flag M2 (#F3165, Sigma Aldrich); mouse anti-GAPDH clone 6C5
(#ab8245, Abcam); mouse anti-GFP (#632375; Clontech); mouse anti-turboGFP
clone OTI2H8 (#TA150041; Origene); mouse anti-HA.11 clone 16B12
(#MMS-101P, Covance), mouse anti-LAMP1 clone H4A3 (obtained from
Developmental Studies Hybridoma Bank, University of Iowa); mouse anti-LC3
clone 5F10 (#0231, Nanotools); mouse anti-c-myc clone 9E10 (#11667203001;
Roche); mouse anti-V5 (#46-0705, Invitrogen/Life Technologies); mouse
anti-TFEB (#MBS120432, MyBioSource); mouse anti-ubiquitin P4D1 (#3936, Cell
Signaling); rabbit anti-actin (#A2066, Sigma Aldrich); rabbit anti-ATG16L
(#PM040, MBL); rabbit anti-ATP13A2 (#5879, Cell Signaling); rabbit anti-GFP
(#632592, Clontech); rabbit anti-LAMP1 (#9091, Cell Signaling); rabbit anti-LC3
(#NB 100-2220, Novus Biologicals); rabbit anti-phosphoSer2481 mTOR (#2974,
Cell Signaling); rabbit anti-phosphoThr389 p70S6kinase (#9234) and anti-total
p70S6kinase (#9202) (Cell Signaling); rabbit anti-MYCBP2 (#ab86078, Abcam);
rabbit anti-TFEB (#4240, Cell Signaling); rabbit anti-phosphoSer1387-TSC2
(#5584), anti-phosphoThr1462-TSC2 (#3617) and anti-total TSC2 (#4308) (Cell
Signaling); rabbit anti-K48-linkage-speciﬁc polyubiquitin (#4289, Cell Signaling);
rabbit anti-ZNF306/ ZKSCAN3 (#AV33609; Sigma); goat anti-Lamin B M20
(#sc-6217, Santa Cruz Biotechnology); goat anti-SYT11 N-15 (#sc-162280, Santa
Cruz Biotechnology); goat anti-TFEB (#ab2636; Abcam); anti-mouse (#NA931V)
and anti-rabbit (#NA934V) horseradish peroxidise (HRP)-conjugated secondary
antibodies (GE Healthcare); anti-goat horseradish peroxidise (HRP)-conjugated
secondary antibody (#611620, Invitrogen/Life Technologies); Alexa Fluor
488- (#A11001) and Alexa Fluor 568- (#A11004) conjugated goat anti-mouse
(Invitrogen/Life Technologies); Alexa Fluor 488- (#A11008) and Alexa Fluor 568-
(#A11036) conjugated goat anti-rabbit secondary antibodies (Invitrogen/Life
Technologies). For western blotting, all the primary antibodies were used at a
dilution of 1:1,000 (overnight incubation at 4 C), unless otherwise stated, and the
secondary antibodies used at a dilution between 1:2,000 and 1:5,000 (1 h of incu-
bation at room temperature), while for immunoﬂuorescence primary antibodies
were used at a range of 1:50 to 1:200 (overnight incubation at 4 C) and secondary
antibodies used at a dilution of 1:400 (1 h of incubation at room temperature in the
dark). The following constructs were also used in this work: empty pEFGP;
pEGFP-LC3; pEGFP-SYT11 (kindly provided by Dr Stefan Pulst)35;
pCMV6-SYT11-TurboGFP (RG205445, Origene); pcDNA3.1-myc-His
(Invitrogen); pcDNA3.1-SYT11/myc-His; SYT11 promoter-GLuc/SEAP pEWZX-
PG04 (HPRM12158-PG04, GeneCopoeia); pEGFP-a-synuclein A53T; pcDNA3.1;
pcDNA3.1 ATP13A2 WT, pcDNA3.1 ATP13A2 delC (3057 delC) mutant and
pcDNA3.1 ATP13A2 i16 (1632_1653dup22) mutant (all V5-tagged) (kindly
provided by Dr Christian Kubisch)7; empty pCMV; pCMV TFEB WT-3xFlag and
pCMV TFEB S142A-3xFlag constitutively active mutant (kindly provided by Dr
Andrea Ballabio)20; pcDNA3 Flag-TSC2 (#14129, Addgene)55; pcDNA3.1
HA-ubiquitin; pSpCas9n(BB)-2A-GFP (PX461) vector (#48410, Addgene). The
following inhibitors were used in this work: Baﬁlomycin A1 (Millipore); Torin-1
(Millipore); Cycloheximide (Sigma Aldrich); MG132 (Sigma Aldrich); Rapamycin
(Sigma Aldrich). Pre-designed siRNAs (SMARTpool and/or set of deconvoluted
oligos ON-TARGETplus4Non-targeting Control #D-001810-10; SYT11 #L-
018292, ATP13A2 #L-008601, MYCBP2 #L-006951; TFEB #L-009798; ZKSCAN3
#L-014607) were obtained from Dharmacon—Thermo Scientiﬁc. Pre-designed
pLKO.1 shRNAs vectors from The RNAi Consortium (TRC) (empty vector
control—#RHS4080, Dharmacon; eGFP shRNA control—#SHC005, Sigma
Aldrich; mouse SYT11—#RMM4534-EG229521, Thermo Scientiﬁc; mouse
ATP13A2 shRNAs—#SHCLNG-NM_029097, Sigma Aldrich) were also used in
this work. Although all the shRNAs provided by TRC were validated, some were
selected and used to perform most of the experiments (SYT11: TRCN0000106535
(#A) and TRCN0000093552 (#B); ATP13A2: TRCN0000101717 (#A),
TRCN0000101718 and TRCN0000101719 (#B)).
Mutagenesis and sub-cloning. Mutagenesis of the human WT SYT11
promoter-GLuc-SEAP vector (GeneCopoeia) (CLEAR-Site 2 in SYT11 promoter;
CTCAAGTGAT4CAAAAGAAAT) was generated with QuikChange Multi
Site-Directed Mutagenesis Kit (Agilent Stratagene), according to manufacturer’s
instructions, using the set of primers listed in Supplementary Table 1. DPN I
digestion was performed after PCR and XL-10 gold-competent cells were
transformed. After sequencing, SYT11 mutant promoter from a positive clone was
subcloned into the original vector using EcoR I and Hind III restriction enzymes
(New England BioLabs Inc.) followed by ligation using T4 DNA ligase (New
England BioLabs Inc.). The ﬁnal vector was conﬁrmed by sequencing. For the
production of pcDNA3.1-human SYT11/myc-His, human SYT11 complementary
DNA was subcloned into pcDNA3.1/myc-His (Invitrogen) using EcoR I and Xho I
(New England BioLabs Inc.) for restriction and T4 DNA ligase (New England
BioLabs Inc.) for ligation. Efﬁcient subcloning and protein expression were
conﬁrmed by sequencing and western blotting against c-myc, respectively.
Isolation and culture of primary cortical neurons. All mouse experiments were
performed with personal and project licences granted by the UK Home Ofﬁce and
with the approval of the University of Cambridge committee for animal studies.
Primary cortical neurons were isolated from C57BL/6 mice (Jackson Laboratories)
embryos at E16.5. Brieﬂy, brains were harvested and placed in PBS/glucose where
the meninges were removed and the cerebral cortices were dissected. After
mechanical dissociation using sterile micropipette tips, dissociated neurons were
resuspended in PBS/glucose and collected by centrifugation. Viable cells were
seeded on poly-ornithine-coated 6- or 12-multiwell plates. Cells were cultured in
Neurobasal medium supplemented with 2mM glutamine, 200mM B27 supple-
ment and 1% Penicillin–Streptomycin at 37 C in a humidiﬁed incubator with 5%
CO2. One half of the culture medium was changed every 2 days until treatment/
infection. After 5 days of in vitro culturing, differentiated neurons were infected
with lentiviral particles56.
Generation of CRISPR/Cas9 HeLa cell line for ATG16L1. HeLa CRISPR/Cas9
ATG16L1 knockout cell line was generated using double nicking to minimize off
target cleavage as previously described57,58. Brieﬂy, pairs of guided RNAs (gRNAs)
nicking the ﬁrst exon of ATG16L1 (192-211 and 146-166) were designed using the
CRISPR design tool available at Zhang Lab website (http://www.genome-
engineering.org/crispr/). gRNAs with overhangs were annealed (without
phosphorylation) and cloned into BbsI-digested pSpCas9n(BB)-2A-GFP (PX461)
vector (#48140, Addgene) as described before58. Ligation was performed using T4
DNA ligase based on ‘ELAN’ method59. HeLa cells were subsequently transfected
with pairs of gRNAs cloned into PX461 or with empty PX461. Two days after
transfection, GFP-positive cells were single-cell sorted into 96-well plates using
ﬂuorescent activated cell sorting (FACS). Clones were expanded and those where
almost undetectable levels of ATG16L1 and autophagy activity were observed were
selected. While it should be noticed that residual ATG16L1 levels might still be
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observed, for the purpose of our experiments these are autophagy-incompetent
clones.
GFP-P62 clearance assay. GFP-P62 HEK293 Flp-In T-REx cells54 (gift from
Dr Terje Johansen) were used to evaluate P62 clearance, an indicator of the
autophagic ﬂux. GFP-P62 expression under the control of the CMV/TetO2
promoter was induced by adding 1 mgml 1 tetracycline to the culture medium for
24 h. Cells were then washed twice with PBS to switch off the transgene expression
and kept in full medium without tetracycline for 18 h. P62 clearance was
determined by blotting the cell lysates against GFP and performing T18/T0 (h)
ratio of the densitometry measurements of GFP-P62 bands.
Transfection. Trans IT-2020 reagent (Mirus) was used for DNA transfections,
while Lipofectamine 2000 (Invitrogen/Life Technologies) was used for siRNA
transfections, according to the manufacturer’s instructions. After transfection, cells
were maintained in full medium. For knockdown experiments, unless otherwise
speciﬁed in ﬁgure legends, cells were transfected with 50 nM siRNA followed by
another 50 nM siRNA transfection after 48 h. Cells were split once in between both
transfections and harvested after 4 days of transfection.
a-synuclein A53Tassay. Cells were transfected with 1.5 mg of pEGFP-a-synuclein
A53T and 0.5 mg of empty pEGFP per well of a six-well plate. Forty-eight hours
after transfection, cells were lysed and used to analyse GFP-a-synuclein A53T and
GFP levels by western blotting. Ratio between both signals was calculated.
shRNA lentivirus production and infection. shRNA lentiviral particles were
produced and transduced following The RNAi Consortium (TRC) protocols.
Brieﬂy, HEK-293T packaging cells growing in 100mm dishes were transfected at
50–60% of conﬂuence with a mix of 2.5 mg psPAX2 vector (packaging vector),
270 ng pMD2.G vector (envelope vector) and 2.7 mg hairpin-pLKO.1 vector.
TransIT-LT1 (Mirus) was used as transfection reagent according to the
manufacturer’s instructions. After transfection, cells were cultured in high-serum
medium. Cell culture medium was harvested 40 h later and replaced by high-serum
medium; this step was repeated two to three times for intervals of 24 h. Viral preps
were then concentrated by centrifugation at 160,100g for 90min. Depending on the
cell type, different viral titres were added to the cells in the presence of 4 mgml 1
polybrene (Sigma Aldrich) and were incubated overnight. 24 h later, medium was
replaced by full medium and cells were further incubated for an additional 3–4
days before testing the knockdown effects.
Western blot. Cells were washed with ice-cold PBS and directly lysed with
2 Laemmli buffer and boiled at 95 C for 5min or lysed with RIPA buffer
(50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate
monohydrate, 0.1% SDS, supplemented with protease and phosphatase inhibitors
cocktails (Roche)). When lysed in RIPA buffer, cells were incubated on ice for
30min, centrifuged at 16,100 g for 10min and protein concentration of super-
natants was determined using a Bradford assay kit (Bio-Rad). Lysates were then
denatured with 2 Laemmli buffer and boiled at 95 C for 5min. Cell extracts
were resolved by SDS–PAGE and transferred electrophoretically onto poly-
vinylidene ﬂuoride (PVDF) membranes. The membranes were blocked with 5%
nonfat milk in PBS-T (PBS, 0.2% Tween 20) and probed for the proteins of interest,
using speciﬁc primary and HRP-conjugated secondary antibodies, according to the
respective manufacturer’s instructions. Immunoreactive bands were visualized with
an ECL system (Pierce, Thermo Scientiﬁc). For detection of very high molecular
weight proteins (for example, MYCBP2), precast NuPAGE Novex 3-8% Tris-
Acetate protein gels (Thermo Fisher Scientiﬁc) were used according to the man-
ufacturer’s instructions. Densitometric analysis on the immunoblots was per-
formed using Image J. Full blot images are shown in Supplementary Fig. 7.
Cytosolic/nuclear fractionation. Cells were washed twice with ice-cold PBS and
lysed with four packed cell volumes of Buffer A (10mM HEPES, 10mM KCl,
0.1mM EDTA, 0.4% NP-40, 1mM DTT and protease/phosphatase inhibitors
cocktail) and incubated on ice for 30min. Cell lysates were centrifuged at 16,100g
at 4 C for 10min. Supernatants containing cytosolic proteins were harvested and
nuclear pellets were resuspended in 3.5 packed cell volumes of Buffer B (20mM
HEPES, 0.4 M NaCl, 1mM EDTA, 10% glycerol, 1mM DTT and 1 protease
inhibitor cocktail) and incubated for 1 h on ice. After centrifugation at 16,100g for
10min at 4 C, supernatants containing the nuclear proteins were collected. Both
cytosolic and nuclear fractions were denatured and used to perform immunoblot
against TFEB, ZKSCAN3, Lamin-B and GAPDH. Protein concentration was
determined using the Bradford assay (Bio-Rad).
Immunoprecipitation and mass spectrometry. Cells in 60mm dishes were
washed twice with PBS and collected in ice-cold PBS. Pellets were resuspended in
200ml of lysis buffer (20mM Tris-HCl, pH 7.2, 150mM NaCl, 2mM MgCl2, 0.5%
NP-40, protease/phosphatase inhibitors cocktails, and further supplemented with
1mM PMSF, 10mM iodoacetamide for the ubiquitination assays). Lysates were
incubated on ice for 30min and cleared by centrifugation at 16,100g for 10min.
Supernatants were transferred to new tubes; 1/10 of the sample was kept as whole
cell lysate/input control, while the remaining lysate was overnight incubated with
primary antibodies at 4 C with gentle agitation. Thereafter, Dynabeads-protein G
(Life Technologies) or Protein A Sepharose beads (for TSC2 ubiquitination assays;
GE Healthcare) were added to the samples and incubations proceeded at 4 C for
2 h. Beads were washed three times with lysis buffer and the immunoprecipitated
proteins were eluted and denatured with 2 Laemmli buffer and boiled at 100 C.
Samples were loaded on SDS–PAGE and western blot analyses were performed.
Considering that the levels of TSC2 and SYT11 are affected by the genetic
manipulations described in the ﬁgures, we adjusted the immunoprecipitations
loading volumes, keeping the levels of the immunoprecipitated protein even
(using the levels of the respective protein in the inputs as reference), to assess
protein ubiquitination.
For mass spectrometry, samples were resolved B1 cm into a pre-cast
SDS–polyacrylamide gel, the entire lane excised and cut into four equal slices.
Proteins were reduced and alkylated, and subsequently digested in-gel using
trypsin. The resulting peptides were analysed by LC-MS/MS in a DDA manner
using a Q Exactive (Thermo Scientiﬁc) coupled to a RSLC3000 nanoUPLC
(Thermo Scientiﬁc). Raw ﬁles were converted to mzML using MSconvert
(ProteoWizard) and submitted to MASCOT 2.3.0 to search a human Uniprot
database (20,264 entries, downloaded 09/06/14). Peptide and protein validation
was performed using Scaffold 4.3.2. Likely hits required a minimum of 95%
probability and proteins a minimum of 90% probability and two peptides.
Immunoﬂuorescence and microscopy. Cells growing in coverslips were ﬁxed
with 4% paraformaldehyde (unless otherwise stated). The ﬁxed samples were
permeabilized with 0.1% Triton X-100 (v/v) for 10min and blocked with 10% goat
serum or 2% BSA in PBS for 1 h prior to overnight incubation with primary
antibodies (concentration ranging from 1:50 to 1:200). The samples were then
washed three times with PBS and incubated with 1:400 Alexa Fluor 488- or Alexa
Fluor 568-conjugated goat anti-mouse or anti-rabbit secondary antibodies
(Invitrogen/Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature.
The samples were then washed three times with PBS and once with water and
mounted with ProLong Antifade reagent containing DAPI (Invitrogen/Life
Technologies). The samples were imaged by LSM170 confocal microscopy (Zeiss).
ImageJ and Photoshop (Adobe) were used for further analysis and processing of
confocal images. Automated counting and analysis of area and intensity of
autophagosomes and autolysosomes using a HeLa stable cell line expressing mRFP-
EGFP-LC3 was performed using an ArrayScan VTi HCS system (Cellomics).
Proximity ligation assay. The proximity ligation assay kit was obtained from
Sigma Aldrich and used according to manufacturer’s instructions. Brieﬂy, cells
growing in coverslips were ﬁxed with 4% paraformaldehyde in PBS, permeabilized
with 0.1% Triton X-100 in PBS and blocked with 2% BSA in PBS. Subsequently,
cells were incubated with primary antibodies (1 h at room temperature), which was
followed by incubation of cells with secondary antibodies conjugated to oligonu-
cleotide primers, also designated proximity ligation assay probes MINUS and PLUS
(1 h at 37 C). The primers were then ligated (30min at 37 C) and then rolling
circle ampliﬁcation (100min at 37 C) was used to create a reaction product that is
observable by microscopy due to hybridization of ﬂuorescently labelled nucleotides.
Successful production of a DNA product requires that the primary antibodies bind
their respective antigens and reside within 40 nm of each other. Coverslips were
mounted on slides and imaged by epiﬂuorescence microscopy.
Cathepsin-L activity. Brieﬂy, cells were lysed in cold CL lysis buffer (Abcam) and
incubated on ice for 10min. The lysates were cleared by centrifugation at 16,100g
for 5min at 4 C. To 40–50 mg of protein (in 50 ml), we added 50ml of CL reaction
buffer (Abcam) and 2 ml of 10mM Ac-FR-AFC ﬂuorogenic substrate (Abcam).
Samples were incubated for 2 h at 37 C and ﬂuorescence was measured using a
plate reader and the following settings: lex 400 nm; lem 505 nm. Fluorescence was
measured using a Versamax Tunable microplate reader (Molecular Devices).
Cell viability assay. CellTiter-Glo Luminescent Cell Viability assay (Promega) was
used to assess cell viability, according to manufacturer’s instructions. This assay
determines the number of viable cells in culture by quantifying the ATP present,
which reﬂects the number of metabolically active cells. Brieﬂy, cells seeded in
96-well plates were incubated with a volume of CellTiter-Glo reagent (CellTiter-
Glo substrate previously reconstituted in CellTiter-Glo buffer) equal to the volume
of cell culture medium present in each well. Contents were mixed for 2min on an
orbital shaker to induce cell lysis and subsequently incubated at room temperature
for 10min to stabilize luminescent signal. Homogenates were then transferred to a
white opaque 96-well plate and luminescence was measured with an integration
time of 0.5 s per well using GLOMAX 96-microplate luminometer (Promega).
Results were normalized towards protein concentration.
Annexin V-FITC apoptosis detection assay. Cells were gently trypsinized and
washed once with serum-containing media. 2.5 105 cells were collected by
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centrifugation and re-suspended in 500 ml of binding buffer. Annexin V-FITC
(5ml) and propidium iodide (PI; 5 ml) were then added to the cell suspension and
incubation proceeded for 5min at room temperature in the dark (Annexin
V-FITC/PI Kit, Abcam). Annexin V-FITC binding and PI staining were analysed
by ﬂow cytometry using FL1 (ex¼ 488 nm; em¼ 530 nm) and FL2 (ex¼ 488 nm;
em¼ 585 nm) detectors, respectively, and appropriate compensation settings
(FACSCalibur). Annexin V-FITC(-)/PI(-) represent viable cells, Annexin
V-FITC(þ )/PI(-) represent early apoptotic cells and Annexin V-FITC(±)/PI(þ )
represent late apoptotic/necrotic cells.
Luciferase reporter assay. Cell culture medium from cells transfected with
human WT SYT11 promoter-GLuc-SEAP (pEZX-PG04; GeneCopoeia) or
CLEAR-site 2 mutated SYT11 promoter-GLuc-SEAP vectors for 48 h was collected.
Secrete-Pair Dual Luminescence Assay Kit (GeneCopoeia) was used, according to
manufacturer’s instructions, to analyse the activities of Gaussia Luciferase (GLuc)
and secreted alkaline phosphatase (SEAP) in cell culture medium. Both GLuc and
SEAP are secreted reporter proteins. SYT11 promoter controls GLuc reporter gene
expression, while SEAP is controlled by a cytomegalovirus (CMV) promoter. SEAP
expression was used as a normalization factor (internal standard control). Brieﬂy,
10ml of culture medium samples were pipetted into a 96-well white opaque plate
(samples need to be heated at 65 C for 15min when measuring SEAP expression),
which were supplemented with 100 ml of GLuc assay working solution (buffer GL-S
in waterþ substrate GL) or SEAP assay working solution (buffer AP in waterþ
substrate AP). Homogenates were incubated at room temperature for 1min (GLuc)
or 5min (SEAP) and luminescence was subsequently measured (GLOMAX
96-microplate luminometer, Promega). The ratio of luminescence intensities (RLU,
relative light unit) of GLuc over SEAP was calculated for each sample.
Endosomal/lysosomal pH measurement. Endosomal/lysosomal pH was deter-
mined using the pH-sensitive LysoSensor Green DND-189 dye (Invitrogen/Life
Technologies) at a working concentration of 1 mM, according to the manufacturer’s
instructions. Brieﬂy, cells were incubated with 1 mM LysoSensor Green DND-189
in normal cell culture medium for 1 h at 37 C. For the calibration curve, cells were
incubated with pH-ﬁxed MES buffer (5mM glucose, 20mM MES, 1mM CaCl2,
1mM MgCl2, 130mM NaCl and 10mM KCl; pH 3.0, 4.0, 5.0 and 6.0) in the
presence of 10 mM nigericin (Sigma Aldrich) and 10mM monensin (Sigma
Aldrich). Fluorescence was measured with a Versamax Tunable microplate reader
(Molecular Devices) (lex 443 nm, lem 505 nm). Alternatively, pH determination of
acidic organelles was assessed using the ratiometric LysoSensor Yellow/Blue DND-
160 (Invitrogen/Life Technologies) probe at a ﬁnal concentration of 1 mM, which
produces blue ﬂuorescence in a neutral environment but shifts to yellow
ﬂuorescence in more acidic compartments (pKaE4.2), according to the manu-
facturer’s instruction. Brieﬂy, 80–90% conﬂuent cells seeded on a glass bottom
culture dish (MatTek Corporation) were loaded with the LysoSensor tracer for
30min at 37 C, washed twice with medium and live imaged immediately at 37 C.
Cells were excited at 365 nm and images were taken at 450 and 510 nm of emission,
respectively. ImageJ was used for analysis60.
Real-time PCR. Total RNA was puriﬁed using TRIzol (Invitrogen/Life Technol-
ogies) or using RNeasy Mini kit columns (Qiagen), according to the manufacturer’s
instructions. Total RNA samples were then treated with RNase-free DNase I
(Invitrogen/Life Technologies) to avoid genomic DNA contamination. SuperScript
III First Strand Synthesis kit (Invitrogen/Life Technologies) was used to synthesize
the ﬁrst cDNA strand according to the manufacturer’s instructions. For real-time
PCR, SYBR Green PCR master mix reagent (Invitrogen/Life Technologies) was
used and cDNA ampliﬁcation was performed according to the manufacturer’s
protocols. GAPDH was used as housekeeping gene and the set of primers listed in
Supplementary Table 1 were used for single ampliﬁcation reactions. All the
real-time PCR analyses were conducted on a 7900HT Fast Real-Time PCR System
(Applied Biosystems) and relative quantitation was performed based on the DDCT
method. Results represent fold induction compared with the respective control.
Chromatin immunoprecipitation. HeLa cells (1 108 per condition) were
incubated with 1% formaldehyde (cross-linker) in cell culture medium for 10min
at room temperature. To stop the crosslinking, cells were subsequently treated with
0.215M Glycine for 5min at room temperature and then washed twice with PBS.
Cells were lysed in buffer A (10mM Tris pH 8.0, 10mM NaCl, 0.2% NP40
supplemented with 10mM NaBu and protease/phosphatase inhibitors cocktail) for
10min on ice. The nuclei were recovered by centrifuging the lysates at 3,000g for
5min at 4 C, resuspended in buffer B (50mM Tris pH 8.0, 10mM EDTA, 1% SDS
supplemented with 10mM NaBu and protease/phosphatase inhibitors cocktail)
and incubated for 10min on ice. Samples were then diluted 2 in buffer C
(20mM Tris pH 8.0, 2mM EDTA, 150mM NaCl, 1% Triton X100, 0.01% SDS
supplemented with 10mM NaBu and protease/phosphatase inhibitors cocktail)
before intermittent sonication for 10min at 4 C. Chromatin was then cleared
using protein A-sepharose (GE Healthcare) and equal amounts were incubated
overnight at 4 C on a rotator either with rabbit anti-TFEB antibody (Cell
Signaling) or mouse anti-TFEB antibody (MyBioSource), anti-Histone H3 (Abcam)
or anti-mouse- or anti-rabbit-unspeciﬁc IgGs (Sigma Aldrich). Immunocomplexes
were subsequently isolated using protein A-sepharose (GE Healthcare) for 2 h at
4 C, washed twice with buffer D (20mM Tris pH 8.0, 2mM EDTA, 50mM NaCl,
1% Triton X-100, 0.1% SDS), once with buffer E (10mM Tris pH 8.0, 1mM EDTA,
0.25 M LiCl, 1% NP-40, 0.1% sodium deoxycholate monohydrate) and once with
TE buffer. Samples were then eluted using buffer F (100mM NaHCO3, 1% SDS).
The crosslinking was reversed by treating the samples with RNase A and 0.3 M
NaCl overnight at 67 C. RNase A was then inactivated by incubating the samples
with proteinase K (Fisher Scientiﬁc) for 2 h at 45 C. Samples were then cleaned
using the Qiaquick PCR puriﬁcation kit (Qiagen) and used for real-time PCR
analysis using the standard curve method. The primers used for the ampliﬁcation
of the putative TFEB-binding sites are listed in Supplementary Table 1.
Statistical analysis. Signiﬁcance levels for comparisons between groups were
determined with unpaired or paired two-tailed Student’s t-test using GraphPad
Prism 5 (GraphPad Software) or Excel (Microsoft Ofﬁce), where appropriate.
Quantiﬁcations are plotted as mean±s.d. or s.e.m.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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